ANTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.9M
-15.6%
10.6M
+13.3%
9.3M
-7.2%
10.0M
+39.1%
7.2M
R&D
6.0M
-10.7%
6.7M
-2.0%
6.9M
-1.7%
7.0M
+118.8%
3.2M
SG&A
2.9M
-24.2%
3.8M
+56.3%
2.4M
-19.8%
3.0M
-24.3%
4.0M
Operating Income
-8904000
+15.6%
-10551000
-13.3%
-9316000
+7.2%
-10040000
-39.1%
-7216000
EBITDA
-8904000
+15.6%
-10551000
-13.3%
-9316000
+7.2%
-10040000
-39.1%
-7216000
Net Income
-8185000
+18.4%
-10028000
-15.1%
-8710000
+6.9%
-9353000
-44.7%
-6462000
EPS (Basic)
$-0.18
+37.9%
$-0.29
+0.0%
$-0.29
+6.5%
$-0.31
-47.6%
$-0.21
EPS (Diluted)
$-0.18
+37.9%
$-0.29
+0.0%
$-0.29
+6.5%
$-0.31
-47.6%
$-0.21
Shares (Diluted)
44.8M
+31.4%
34.1M
+12.2%
30.4M
+0.3%
30.3M
+0.3%
30.2M
AN2 Therapeutics (ANTX) โ€” Financials